Mirjam Crul

1.9k total citations
75 papers, 1.2k citations indexed

About

Mirjam Crul is a scholar working on Oncology, Occupational Therapy and Molecular Biology. According to data from OpenAlex, Mirjam Crul has authored 75 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 25 papers in Occupational Therapy and 19 papers in Molecular Biology. Recurrent topics in Mirjam Crul's work include Safe Handling of Antineoplastic Drugs (25 papers), Pharmaceutical studies and practices (17 papers) and Medical Device Sterilization and Disinfection (9 papers). Mirjam Crul is often cited by papers focused on Safe Handling of Antineoplastic Drugs (25 papers), Pharmaceutical studies and practices (17 papers) and Medical Device Sterilization and Disinfection (9 papers). Mirjam Crul collaborates with scholars based in Netherlands, United States and Germany. Mirjam Crul's co-authors include Jos H. Beijnen, Jan H.M. Schellens, G.J.M. de Klerk, Robert C.A.M. van Waardenburg, Hilde Rosing, Marc Maliepaard, J. H. M. Schellens, Jeany M. Rademaker-Lakhai, Nico van Zandwijk and Paul Baas and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

Mirjam Crul

66 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mirjam Crul Netherlands 18 490 447 187 156 127 75 1.2k
Bertrand Pourroy France 17 331 0.7× 294 0.7× 78 0.4× 51 0.3× 64 0.5× 47 823
C Ardiet France 16 240 0.5× 324 0.7× 87 0.5× 71 0.5× 79 0.6× 39 694
Milly E. de Jonge Netherlands 14 219 0.4× 282 0.6× 99 0.5× 38 0.2× 120 0.9× 17 867
C Torrance United Kingdom 22 722 1.5× 441 1.0× 160 0.9× 126 0.8× 13 0.1× 35 1.6k
Christopher James United States 17 255 0.5× 169 0.4× 83 0.4× 24 0.2× 84 0.7× 49 993
Shu Cao United States 23 478 1.0× 502 1.1× 209 1.1× 18 0.1× 19 0.1× 114 1.5k
Rosa Lerose Italy 17 406 0.8× 360 0.8× 227 1.2× 7 0.0× 40 0.3× 34 1.1k
John A. Benvenuto United States 14 226 0.5× 279 0.6× 76 0.4× 33 0.2× 46 0.4× 33 589
Eli Dijkers Netherlands 10 232 0.5× 555 1.2× 250 1.3× 7 0.0× 76 0.6× 22 1.3k
Martin Czejka Austria 15 158 0.3× 245 0.5× 61 0.3× 18 0.1× 49 0.4× 70 739

Countries citing papers authored by Mirjam Crul

Since Specialization
Citations

This map shows the geographic impact of Mirjam Crul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mirjam Crul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mirjam Crul more than expected).

Fields of papers citing papers by Mirjam Crul

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mirjam Crul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mirjam Crul. The network helps show where Mirjam Crul may publish in the future.

Co-authorship network of co-authors of Mirjam Crul

This figure shows the co-authorship network connecting the top 25 collaborators of Mirjam Crul. A scholar is included among the top collaborators of Mirjam Crul based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mirjam Crul. Mirjam Crul is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Santos, Mónica S.F., Ana R. Ribeiro, Lucie Bláhová, et al.. (2025). Surface Wipe Sampling of Hazardous Medicinal Products: A European Interlaboratory Comparison Study. Drug Testing and Analysis. 17(10). 1955–1964.
2.
Westerman, Elsbeth M., et al.. (2025). Particulate contamination in parenteral fluid from glass ampoules: compliance assessment and comparative analysis of needle types and ampoule-breaking strategies. European Journal of Pharmaceutical Sciences. 212. 107184–107184.
3.
Labots, Mariëtte, et al.. (2024). Reducing renal function assessment prior to platinum-based chemotherapy: a real-world evaluation. Acta Oncologica. 63. 169–174. 3 indexed citations
4.
5.
6.
Crul, Mirjam, et al.. (2023). A Tool for Deprescribing Antithrombotic Medication in Palliative Cancer Patients: A Retrospective Evaluation. Journal of Pain & Palliative Care Pharmacotherapy. 38(1). 20–27. 4 indexed citations
7.
Nejadnik, M. Reza, et al.. (2023). Aggregate Formation and Antibody Stability in Infusion Bags: The Impact of Manual and Robotic Compounding of Monoclonal Antibodies. Journal of Pharmaceutical Sciences. 113(4). 1029–1037. 2 indexed citations
8.
Crul, Mirjam, et al.. (2022). An economic evaluation of vial sharing of expensive drugs in automated compounding. International Journal of Clinical Pharmacy. 44(3). 673–679. 9 indexed citations
9.
Lawler, Mark & Mirjam Crul. (2022). Data must underpin our response to the covid-19 pandemic’s disastrous impact on cancer. BMJ. 376. o282–o282. 6 indexed citations
10.
Crul, Mirjam, et al.. (2021). Deprescribing in palliative patients with cancer: a concise review of tools and guidelines. Supportive Care in Cancer. 30(4). 2933–2943. 13 indexed citations
11.
Swart, Eleonora L., et al.. (2021). Assessment of occupational exposure to nebulized isopropyl alcohol as disinfectant during aseptic compounding of parenteral cytotoxic drugs in cleanrooms. Journal of Occupational and Environmental Hygiene. 18(8). 361–368.
12.
Crul, Mirjam, et al.. (2019). Bevacizumab for Intravitreal Injection: Impact of Sub-Visible Particles on the Shelf-Life of Repackaged Bevacizumab. Journal of Ocular Pharmacology and Therapeutics. 35(6). 372–375. 9 indexed citations
13.
Franssen, Eric J. F., et al.. (2019). Microbiological performance of a robotic system for aseptic compounding of cytostatic drugs. European Journal of Pharmaceutical Sciences. 130. 181–185. 17 indexed citations
14.
Sombogaard, Ferdi, Eric J. F. Franssen, Wim Terpstra, et al.. (2018). Outcome effects of antiretroviral drug combinations in HIV-positive patients with chemotherapy for lymphoma: a retrospective analysis. International Journal of Clinical Pharmacy. 40(5). 1402–1408. 8 indexed citations
15.
Crul, Mirjam, et al.. (2012). Anticholinergic toxicity after the ingestion of serotonergic 'magic mushrooms'. Pure Amsterdam UMC. 16(3). 93–96. 1 indexed citations
16.
Crul, Mirjam, et al.. (2012). Preparation of monoclonal antibodies: Practice across Europe. Pure Amsterdam UMC. 5. 6–8. 3 indexed citations
17.
Rademaker-Lakhai, Jeany M., Mirjam Crul, Dick Pluim, et al.. (2005). Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Anti-Cancer Drugs. 16(9). 1029–1036. 6 indexed citations
18.
Crul, Mirjam, G.J.M. de Klerk, Louis M. Weiner, et al.. (2002). Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors. European Journal of Drug Metabolism and Pharmacokinetics. 27(1). 61–65. 8 indexed citations
19.
Crul, Mirjam, Hilde Rosing, G.J.M. de Klerk, et al.. (2002). Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. European Journal of Cancer. 38(12). 1615–1621. 132 indexed citations
20.
Crul, Mirjam, G.J.M. de Klerk, Jos H. Beijnen, & J. H. M. Schellens. (2001). Ras biochemistry and farnesyl transferase inhibitors: a literature survey. Anti-Cancer Drugs. 12(3). 163–184. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bertrand Pourroy Breakdown of academic impact, for papers by C Ardiet Breakdown of academic impact, for papers by Milly E. de Jonge Breakdown of academic impact, for papers by C Torrance Breakdown of academic impact, for papers by Christopher James Breakdown of academic impact, for papers by Shu Cao Breakdown of academic impact, for papers by Rosa Lerose Breakdown of academic impact, for papers by John A. Benvenuto Breakdown of academic impact, for papers by Eli Dijkers Breakdown of academic impact, for papers by Martin Czejka
Rankless by CCL
2026